Simple Summary Metastatic lung cancer represents a heterogeneous population of patients.
Up to half of patients with metastatic lung cancer may be oligometastatic, an intermediate …

Purpose Because of the limitations of current staging systems and evolving definitions, there
are limited data on oligometastatic non-small cell lung cancer (NSCLC) epidemiology. The …

Introduction The oligometastatic state in non-small cell lung cancer (NSCLC) has recently
become well-established. However, the specific definition of oligometastases remains …

Background Major progresses in the systemic treatment of non-small cell lung cancer
(NSCLC) were obtained during the last decade, including the use of immunotherapy and …

Lung metastases are very common, and the lung is the most common site of metastasis.
Although systemic therapy is the gold standard, some patients are offered local therapy for …

Oligometastasis can be regarded as a transition state between early metastasis and
extensive metastasis (limited tumor load, unique tumor biological behavior). Due to the …

In metastatic non-small cell lung cancer (NSCLC), the role of radiotherapy (RT) has been
limited to palliation to alleviate the symptoms. However, with the development of advanced …

Simple Summary Stereotactic body radiation therapy (SBRT) is currently used to treat lung
metastasis, particularly in the setting of oligometastatic disease. Objective of this treatment is …

There is growing interest in exploring use of local therapies in the management of
oligometastatic non-small cell lung cancer (NSCLC) to provide durable local and distant …

Aim To analyze the literature data about lung oligometastatic patients who underwent SBRT
with regard to doses, fractionation, outcomes, response assessment and prognostic factors …